Driving always presents risks, but after dark it's harder to see potential hazards. Plus, the glow of headlights and brake ...

HighTower Advisors LLC raised its stake in shares of Bausch + Lomb Co. (NYSE:BLCO – Free Report) by 14.7% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 24,661 shares of the ...

Learn more about whether Bausch + Lomb Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...

PORTLAND, OR, UNITED STATES, December 19, 2024 /EINPresswire / -- The Over-the-Counter (OTC) Artificial Tears Market is experiencing significant growth, driven by an increasing prevalence of dry eye ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024. The ...

Bausch + Lomb Corporation (NYSE:BLCO; TSX:BLCO), a global leader in eye health products with a market capitalization of $6.55 billion, has been navigating a complex market landscape in 2024.

Bausch + Lomb has a fifty-two week low of $13.16 and a fifty-two week high of $21.69 ... and contact lens care products ...

Bausch + Lomb sells contact lenses, eye drops and other products that generate a steady revenue stream. Bausch Health’s main drug, the gut antibiotic Xifaxan, will likely face generic ...

The company recently invested an additional €90m to expand its capabilities at its contact lens manufacturing plant in ...